Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. reports developments as a clinical-stage life sciences company focused on rebalancing inflammation with its proprietary formulation Gemini. Company updates center on Gemini programs for acute kidney injury, chronic kidney disease, prevention of post-surgical infection, and severe burn-related hyperinflammation and infection.
Recurring announcements include clinical data from the PRIME study, FDA interactions tied to the AKI development pathway, advisory and conference activity, quarterly financial results, warrant inducement financings, proxy matters, and capital-structure actions such as reverse stock splits and Nasdaq listing compliance matters.
Revelation Biosciences (NASDAQ:REVB), a clinical-stage life sciences company, expanded its Acute Kidney Injury (AKI) Advisory Board ahead of a planned Phase 2/3 trial of Gemini. Two internationally recognized leaders in intensive care and nephrology, Dr. Peter Pickkers and Dr. Lui Forni, join to help guide clinical strategy and study design.
Revelation Biosciences (NASDAQ:REVB) issued a corporate update outlining the development path for its lead drug Gemini in acute kidney injury (AKI) and providing 2025 financials.
The FDA agreed that positive data from a single ~300‑patient Phase 2/3 adaptive study using a composite endpoint of death and/or dialysis could support an NDA. Revelation reported $10.7 million in cash at December 31, 2025, believes funding extends into Q1 2027, and reduced annual net loss to $8.9 million.
Revelation Biosciences (NASDAQ:REVB) reported results for the quarter ended March 31, 2026, highlighting an FDA agreement on a single adaptive Phase 2/3 study for Gemini and presentation of additional PRIME Study data at AKI & CRRT 2026. Cash and proceeds totaled $14.1M, including $6.7M from a January warrant inducement. Net cash used in operations was $3.2M and net loss was $3.0M ($2.71 per share). The company believes current resources fund operations through Q1 2027.
Revelation Biosciences (NASDAQ:REVB) announced the formation of an Acute Kidney Injury (AKI) Advisory Board to guide its upcoming Phase 2/3 AKI clinical trial of Gemini. The panel includes internationally recognized nephrologists and critical care physicians led by Principal Investigator Laurence Busse, MD.
The advisory board will inform study design, monitor progress, and support clinical strategy to address the unmet medical need in AKI and advance Gemini's development program.
Revelation Biosciences (NASDAQ:REVB) presented additional PRIME study data showing that a single dose of Gemini durably normalized cellular inflammation and restored immunocompetence in stage 3–4 CKD patient samples.
Key findings: >85% had elevated cytokines predose, >60% had IL-1b/IL-6 elevations, and Gemini reduced elevated cytokines and restored LPS responsiveness through 7 days post‑dose.
Revelation Biosciences (NASDAQ:REVB) will participate in a fireside chat at the 38th Annual Roth Conference on March 24, 2026 at 2:00 p.m. PT in Dana Point, CA.
The event will be webcast live and later archived in the Investors section of Revelation Biosciences' website at www.RevBiosciences.com.
Revelation Biosciences (NASDAQ:REVB) will participate in the 38th Annual Roth Conference in Dana Point, CA, on March 23–24, 2026. CEO James Rolke and CFO Chester S. Zygmont III will attend, and the company will hold a fireside chat on March 24, 2026 at 2:00 p.m. PT.
The fireside chat will be webcast live and later posted in the Investors section at www.RevBiosciences.com. Investors seeking meetings should contact their Roth representative.
Revelation Biosciences (NASDAQ: REVB) reported financial results for the three and twelve months ended December 31, 2025, and clinical progress on its Gemini program.
Highlights: $10.7M cash at year-end, $6.7M net proceeds from January 2026 warrant inducement, positive PRIME clinical study results, and an FDA agreement on a single adaptive Phase 2/3 study for Gemini. Company expects cash runway into Q1 2027.
Revelation Biosciences (NASDAQ:REVB) will implement a 1-for-4 reverse stock split effective the morning of January 28, 2026. Post-split shares will begin trading that day under the existing symbol REVB and a new CUSIP 76135L804 will apply. The reverse split is intended to increase the share price to regain compliance with The Nasdaq Capital Market's minimum bid continued listing requirement. Proportionate adjustments will be made to warrants, restricted stock units and stock options. Fractional shares resulting from the split will be rounded up to the nearest whole share.
Revelation Biosciences (NASDAQ:REVB) entered a definitive agreement for immediate exercise of outstanding warrants to purchase up to 13,065,000 common shares at a reduced exercise price of $0.86 per share, generating roughly $11 million in gross proceeds. Closing is expected on or about January 26, 2026, subject to customary conditions. In exchange, exercising holders will receive new Class J warrants exercisable into up to 26,130,000 shares at $0.86 per share, exercisable only after stockholder approval and for a five-year term thereafter. The company will file a resale registration on Form S-3 within 20 days of closing.